Management and Prognosis of Localized Duodenal Neuroendocrine Neoplasms.


Journal

Neuroendocrinology
ISSN: 1423-0194
Titre abrégé: Neuroendocrinology
Pays: Switzerland
ID NLM: 0035665

Informations de publication

Date de publication:
2021
Historique:
received: 19 11 2019
accepted: 21 04 2020
pubmed: 27 4 2020
medline: 27 1 2022
entrez: 27 4 2020
Statut: ppublish

Résumé

The characteristics, prognostic factors, and management of duodenal neuroendocrine neoplasms (dNEN) are ill-defined, given their rarity. Whether nonsurgical management might be appropriate for patients with nonmetastatic dNEN and a good prognosis, as is the case for pancreatic NEN (pNEN), is unknown. We aimed to describe the management and prognosis of nonmetastatic dNEN patients. All consecutive patients with nonmetastatic dNEN managed between 1981 and 2018 in 2 expert centers were included. Recurrence-free survival (RFS) and factors associated with recurrence were estimated. A total of 145 patients with dNEN were included. Twenty-eight patients with sporadic, nonfunctioning, small (median 7 mm) dNEN underwent endoscopic resection, with a 5-year RFS rate of 89.4%. Local recurrence occurred in 2 patients, who underwent surgery with no new events. The 5-year RFS rate was 87.9% in patients who underwent surgery. Upon univariate analysis, age, size, Ki67 index, and lymph node involvement (LN+) were significantly associated with worse RFS for all dNEN treated (endoscopy/surgery); multivariate analysis found that age, size, and LN+ were associated with worse RFS. Selected nonmetastatic dNEN had a favorable outcome, and a less invasive therapeutic strategy appeared more suitable than oncological surgery.

Identifiants

pubmed: 32335556
pii: 000508102
doi: 10.1159/000508102
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

718-727

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Servane Gay-Chevallier (S)

Hospices Civils de Lyon, Hôpital Édouard Herriot, Service de Gastroentérologie et d'Oncologie Médicale, Lyon, France.

Louis de Mestier (L)

Service de Gastroentérologie et Pancréatologie, Hôpital Beaujon, Université de Paris, Clichy, France.

Julie Perinel (J)

Hospices Civils de Lyon, Hôpital Édouard Herriot, Service de Chirurgie Digestive, Lyon, France.
Université Lyon 1, Université de Lyon, Lyon, France.

Julien Forestier (J)

Hospices Civils de Lyon, Hôpital Édouard Herriot, Service de Gastroentérologie et d'Oncologie Médicale, Lyon, France.

Valérie Hervieu (V)

Université Lyon 1, Université de Lyon, Lyon, France.
Hospices Civils de Lyon, Service de Pathologie Multisite, Site EST, Centre de Biologie et de Pathologie Est, Bron, France.

Philippe Ruszniewski (P)

Service de Gastroentérologie et Pancréatologie, Hôpital Beaujon, Université de Paris, Clichy, France.

Ingrid Millot (I)

Hospices Civils de Lyon, Hôpital Édouard Herriot, Service d'anesthésie-Réanimation, Lyon, France.

Pierre-Jean Valette (PJ)

Université Lyon 1, Université de Lyon, Lyon, France.
Hospices Civils de Lyon, Hôpital Édouard Herriot, Service de Radiologie, Lyon, France.

Mathieu Pioche (M)

Hospices Civils de Lyon, Hôpital Édouard Herriot, Service de Gastroentérologie et d'Oncologie Médicale, Lyon, France.
Université Lyon 1, Université de Lyon, Lyon, France.

Catherine Lombard-Bohas (C)

Hospices Civils de Lyon, Hôpital Édouard Herriot, Service de Gastroentérologie et d'Oncologie Médicale, Lyon, France.

Fabien Subtil (F)

Université Lyon 1, Université de Lyon, Lyon, France.
Hospices Civils de Lyon, Service de Biostatistiques, Lyon, France.
CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Villeurbanne, France.

Mustapha Adham (M)

Hospices Civils de Lyon, Hôpital Édouard Herriot, Service de Chirurgie Digestive, Lyon, France.
Université Lyon 1, Université de Lyon, Lyon, France.

Thomas Walter (T)

Hospices Civils de Lyon, Hôpital Édouard Herriot, Service de Gastroentérologie et d'Oncologie Médicale, Lyon, France, thomas.walter@chu-lyon.fr.
Université Lyon 1, Université de Lyon, Lyon, France, thomas.walter@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH